Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

NEW YORK, NY – January 11, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported a positive dose-response relationship has been observed…

Anavex Issues Statement Addressing Recent Press Releases by Law Firms

NEW YORK, NY – January 8, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today addresses the recent press releases by law firms.…

Anavex Announces Fiscal 2015 Year-End Financial Results

NEW YORK, NY – December 29, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported year-end results for fiscal year 2015. Financial…

ICV Manhattan 2015

Event: Corporate Overview by Christopher U. Missling, PhD, President and Chief Executive Officer Date/Time: Wednesday, December 9, 2015 9:10 a.m. ET Location: Mandarin Oriental, 36th Floor, 80 Columbus Circle Drive, New York, NY